Genetic influences on rheumatoid arthritis in african americans

Zhang Z, Bridges SL, Jr. Pathogenesis of rheumatoid arthritis: role of B lymphocytes. Rheum Dis Clin North Am 2001;27:335–353. Pincus T, Brooks RH, Callahan LF: Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionaire and joint count measures. Ann Intern Med 1994;120(1): 26–34. Seldin MF, Amos CI, Ward R, Gregersen PK: The genetics revolution and the assault on rheumatoid arthritis. Arthritis Rheum 1999;42(6):1071–1079. Goodman AH: Why genes don't count (for racial differences in health). Am J Public Health 2000;90(11):1699–1702. Halushka MK, Fan JB, Bentley K, et al: Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet 1999;22(3):239–247 Schwartz RS: Racial profiling in medical research. N Engl J Med 2001;344(18):1392–1393. Parra EJ, Marcini A, Akey, et al: Estimating African American admixture proportions by use of population-specific alleles. Am J Hum Genet 1998;63(6): 1839–1851. Reitnauer PJ, Go RC, Acton RT, et al: Evidence for genetic admixture as a determinant in the occurrence of insulin-dependent diabetes mellitus in U.S. blacks. Diabetes 1982;31(6 Pt 1):532–537. Glass B, Li CC: The dynamics of racial intermixture—an analysis based on the American Negro. Am J Hum Genet 1953;5:1–19. Acton RT, Harman L, Go RC, Tseng ML, Bias W: Comparison of HLA phenotypes among African Americans from Alabama, Maryland, and North Carolina. Transplant Proc 1993;25(4):2404–2407. Mori M, Beatty PG, Graves M, Boucher KM, Milford EL: HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry. Transplantation 1997;64(7):1017–1027. Vyse TJ, Todd JA: Genetic analysis of autoimmune disease. Cell 1996;85(3):311–318. Stastmy P: Association of the B cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978;298:869–871. Ollier W, Thomson W: Population genetics of rheumatoid arthritis. Rheum Dis Clin North Am 1992;18(4):741–759. Gregersen PK, Silver J, Winchester R The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30: 1205–1213. Rigby AS, Silman AJ, Voelm L, et al: Investigating the HLA component in rheumatoid arthritis: an additive (dominant) mode of inheritance is rejected, a recessive mode is preferred. Genet Epidemiol 1991;8(3):153–175. Rigby AS, Voelm L, Silman AJ: Epistatic modeling in rheumatoid arthritis: an application of the Risch theory. Genet Epidemiol 1993;10(5):311–320. Ollier W, Thomson W: Population genetics of rheumatoid arthritis. Rheum Dis Clin North Am 1992; 18(4):741–759. McDaniel DO, Alarcón GS, Pratt PW, Reveille JD: Most African-American patients with rheumatoid arthritis do not have the rheumatoid antigenic determinant (epitope). Ann Intern Med 1995; 123:181–187. Teller K, Budhai L, Zhang M, Haramati N, Keiser HD, Davidson A: HLA-DRB: 1 and DQB typing of Hispanic American patients with rheumatoid arthritis: the “shared epitope” hypothesis may not apply. J Rheumatol 1996;23(8): 1363–1368. Nichol FE, Woodrow JC: HLADR antigens in Indian patients with rheumatoid arthritis [letter]. Lancet 1981;1(8213):220–221. Sanchez B, Moreno I, Magarino R, et al: HLA-DR w 10 confers the highest susceptibility to rheumatoid arthritis in a Spanish population. Tissue Antigens 1990;36(4): 174–176. Gao X, Gazit E, Livneh A, Stastny P: Rheumatoid arthritis in Israeli Jews: shared sequences in the third hypervariable region of DRB1 alleles are associated with susceptibility. J Rheumatol 1991;18(6): 801–803. Hasstedt SJ, Clegg DO, Ingles L, Ward RH: HLA-1 inked rheumatoid arthritis. Am J Hum Genet 1994;55(4):738–746. Corrélis F, Faure S, Maritinez M, et al: New susceptibility locus for rheumatoid arthritis suggested by agenome-wide linkage study. Proc Natl Acad Sci USA 1998;95(18): 10,746–10,750. Barton A, Eyre S, Myerscough A, et al: High resolution linkage and association mapping identifies a novel rheumatoid arthritis susceptibility locus homologous to one linked to two rat models of inflammatory arthritis. Hum Mol Genet 2001;10(18):1901–1906. Jawaheer D, Seldin MF, Amos CI, et al: A genome-wide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases. Am J Human Genet 2001;68: 927–936. Fishman D, Faulds G, Jeffery R, et al: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102(7):1369–1376. Osiri M, Whitworth W, McNicholl J, Jonas B, Moreland LW, Bridges SL, Jr. A novel single nucleotide polymorphism and five haplotypes in the 5′ flanking region of the IL-6 gene: differences between Caucasians and African-Americans: Arthritis Rheum 1999; 42(Suppl):S196 (abstract). Chu CQ, Field M, Feldmann M, Maini RN: Loca lization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34(9):1125–1132. Brennan FM, Maini RN, Feldmann M: Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin Immunopathol 1998;20(1–2):133–147. Wilson AG, de Vries N, van de Putte LB, Duff GW: A tumour necrosis factor alpha polymorphism is not associated with rheumatoid arthritis. Ann Rheum Dis 1995;54(7):601–603. Campbell DA, Nelson S, Madhok R, Field M, Gallagher G: TNF Nco-1 RFLP is not an independent risk factor in rheumatoid arthritis. Eur J Immunogenet 1994;21(6): 461–467. Field M, Gallagher G, Eskdale J, et al: Tumor necrosis factor locus polymorphisms in rheumatoid arthritis. Tissue Antigens 1997; 50(3):303–307. Vinasco J, Beraun Y, Nieto A, et al: Polymorphism at the TNF loci in rheumatoid arthritis. Tissue Antigens 1997;49(1):74–78. Mulcahy B, Waldron-Lynch F, McDennott MF, et al: Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis. Am J Hum Genet 1996;59(3):676–683. Hajeer AH, Worthington J, Silman AJ, Ollier WE: Association of tumor necrosis factor microsatellite polymorphisms with HLA-DRB1 *04-bearing haplotypes in rheumatoid arthritis patients. Arthritis Rheum 1996;39(7): 1109–1114. Mu H, Chen JJ, Jiang Y, King M-C, Thomson G, Criswell LA: Tumor necrosis factor a microsatellite polymorphism is associated with rheumatoid arthritis severity through an interaction with the HLA-DRB1 share depitope. Arthritis Rheum 1999;42(3):438–442. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW: Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transriptional activation. Proc Natl Acad Sci USA 1997;94(7):3195–3199. Paulus HE, van der Heijde DM, Bulpitt KJ, Gold RH: Monitoring radio graphic changes in early rheumatoid arthritis. J Rheumatol 1996;23(5):801–805. van der Heijde DM, van Leeuwen MA, van Riel PL, van de Putte LB: Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol 1995; 22(9):1792–1796. Corbett M, Dalton S, Young A, Silman A, Shipley M: Factors predecting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years. Br J Rheumatol 1993;32(8):717–723. Nepom GT, Byers P, Seyfried C, et al: HLA genes associated with rheumatoid arthritis: identification of susceptibility alleles using specificoligonucleotide probes. Arthritis Rheum 1989;32(1):15–21. Weyand CM, McCarthy TG, Goronzy JJ: Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J Clin Invest 1995;95:2120–2126. Weyand CM, Xie C, Goronzy JJ: Homozygosity for the HLA-DRB1 allele selects for extraarticular manifestations in rheumatoid arthritis. J Clin Invest 1992;89(6): 2033–2039. Ueno Y, Iwaki Y, Terasaki PI, et al: HLA-DR4 in Negro and Mexican rheumatoid arthritis patients. J Rheumatol 1981;8(5):804–807. Jawaheer D, Thomson W, Mac-Gregor AJ, et al: “Homozygosity” for the HLA-DR shared epitope contributes the highest risk for rheumatoid arthritis concordance in identical twins. Arthritis Rheum 1994;37(5):681–686. Mody GM, Meyers OL: Rheumatoid arthritis in blacks in South Africa. Ann Rheum Dis 1989; 48(1):69–72. Jordan JM: Effect of race and ethnicity on outcomes in arthritis and rheumatic conditions. Curr Opin Rheumatol 1999;11(2):98–103. Karr RW, Rodey GE, Lee T, Schwartz BD: Association of HLA-DRw4 with rheumatoid arthritis in black and white patients. Arthritis Rheum 1980;23(11): 1241–1245. Goel N, Ortel TL, Bali D, et al: Familial antiphospholipid antibody syndrome: criteria for disease and evidence for autosomal dominant inheritance. Arthritis Rheum 1999;42(2):318–327. Alarif LI, Ruppert GB, Wilson R Jr, Barth WF: HLA-DR antigens in Blacks with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 1983;10(2): 297–300. Alarcón GS, Koopman WJ, Acton RT, Barger BO: DR antigen distribution in Blacks with rheumatoid arthritis. J Rheumatol 1983;10(4): 579–583. Alarcón GS, Barger BO, Acton RT, Koopman WJ. HLA antigens and gold toxicity in American blacks with rheumatoid arthritis. Rheumatol Int 1986;6(1):13–17. Adebajo A, Davis P: Rheumatic diseases in A frican blacks. Semin Arthritis Rheum 1994;24(2): 139–153. Mitchell JM, Burkhauser RV, Pincus T: The importance of age, education, and comorbidity in the substantial earnings losses of individuals with symmetric polyarthritis. Arthritis Rheum 1988; 31(3):348–357. Callahan LF, Pincus T, Huston JW III, Brooks RH, Nance EP Jr, Kaye JJ: Measures of activity and damage in rheumatoid arthritis: depiction of changes and prediction of mortality over five years. Arthritis Care Res 1997;10(6):381–394. Sang KG, Cerhan JR, Kolluri S, Ohashi K, Hunninghake GW, Schwartz DA: Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 1997;56(8): 463–469. MacGregor A, Olliver W, Thomson W, Jawaheer D, Silman A: HLA-DRB1 *0401/0404 genotype and rheumatoid arthritis: increased association in men, young age at onset, and disease severity. J Rheumatol 1995;22(6):1032–1036. Plant MJ, Jones PW, Saklatvala J, Olliev WE, Dawes PT: Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. J Rheumatol 1998;25(3):417–426. Weyand CM, Hicok KC, Conn DL, Goronzy JJ: The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992;117:801–806. Brinkman BM, Huizinga TW, Kurban SS, et al. Tumour necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptihility to, or severity of disease? Br J Rheumatol 1997; 36(5):516–521. Kaijzel EL, van Krugten MV, Brinkman BM, et al: Functional analysis of a human tumor necrosis factor alpha (TNF-alpha) promoter polymorphism related to joint damage in rheumatoid arthritis. Mol Med 1998;4(11):724–733. Kleyn PW, Vesell ES: Genetic variation as a guide to drug development. Science 1998;281: 1820–1821. Black AJ, McLeod HL, Capell HA, et al: Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathoprine. Ann Intern Med 1998;129:716–718. Arranz MJ, Collier DA, Munro J et al: Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett 1996;217 (2–3): 177–178. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S: Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993;342(8873):697–699. O'Dell JR, Nepom BS, Haire C, et al: HLA-DRB 1 typing in rheumatoid arthritis: predicting response to specific treatments. Ann Rheum Dis 1998;57(4):209–213. Moreland LW, Baungartner SW, Schiff MH, et al: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337(3):141–147. Moreland LW, Schiff MH, Baumgartner SW, et al: Etane recept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130(6):478–486. Elliott MJ, Maini RN, Feldmann M, et al: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344(8930):1105–1110. Lipsky PE, van der Heijde DM, St Clair EW, et al Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343(22):1594–1602. Kimberly RP, Moreland LW, Wu J, Edberg JC, Weinblatt ME, Blosch C: Occurrence of infection varies with Fc receptor genotype. Arthritis Rheum 1998;41(9) (Suppl): S273 (abstract). Kimberly RP, Moreland LW, Gibson A, Weinblatt M, Bosch C: Susceptibility to infection may vary with TNF promoter genotype. Arthritis Rheum 1998;41(9) (Suppl): S273 (abstract). Bresnihan B: The safety and efficacy of interleukin-1 receptorantagonist in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2001;30(5) (Suppl 2):17–20. Loetscher H, Pan YC, Lahm HW, et al: Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 1990;61(2):351–359. Schall TJ, Lewis M, Koller KJ, et al: Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 1990; 61(2):361–370. Fuchs P, Strehl S, Dworzak M, Himmler A, Ambros PF: Structure of the human TNF receptor 1 (p60) gene (TNFR 1) and localization to chromosome 12pl 3. Genomics 1992;13(1):219–224. Santee SM, Owen-Schaub LB: Human tumor necrosis factor receptor p75/80 (CD 120b) gene structure and promoter characterization. J Biol Chem 1996;271 (35): 21,151–21,159. Drysdale CM, McGraw DW, Stack CB, et al: Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 2000;97(19): 10,483–10,488. Schiff MH: Leflunomide versus methotrexate: a comparison of the European and American experience. Scand J Rheumat Suppl 1999;112:31–35. Sandoval DM, Alarcón GS, Morgan SL: Adverse events in methotrexate-treated rheumatoid arthritis patients. Br J Rheumatol 1995;(34 Suppl 2):49–56. Bathon JM, Martin RW, Fleischmann RM, et al: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343: 1586–1593. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344(22):1659–1667. Exner DV, Dries DL, Domanski MJ, Cohn JN: Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344(18): 1351–1357. Reddy KR, Hoofnagle JH, Tong MJ, et al: Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999;30(3): 787–793. Kinzie JL, Naylor PH, Nathani MG, et al: African Americans with genotype 1 treated with interferon forchronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat 2001; 8(4):264–269.